Sudeep Pharma Ltd (SUDEEPPHRM) — shareholding pattern, promoter holding, financials and share price
About Sudeep Pharma Ltd (SUDEEPPHRM)
Sudeep Pharma Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as SUDEEPPHRM and on the BSE under scrip code 544619. Its ISIN is INE0QPI01025.
Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries. [1]
Sudeep Pharma Limited is a technology‑led manufacturer of excipients and specialty ingredients serving pharmaceutical, food and nutrition industries, with in‑house developed technologies, regulatory certifications (including US‑FDA) and a growing advanced‑materials arm (Sudeep Advanced Materials) focused on battery‑grade iron phosphate for LFP/LMFP markets.
Q3 FY26 results show strong operational momentum: consolidated total income rose 52% YoY to Rs.179.2 crore with EBITDA of Rs.66.8 crore (37.3% margin) and PAT of Rs.47.7 crore (26.6% margin), driven by specialty ingredients strength, NSS contribution, and export growth which now represents ~62% of revenues for the quarter.
Listed peers in Pharmaceuticals: Akums Drugs & Pharmaceuticals Ltd, Blue Jet Healthcare Ltd, Sanofi Consumer Healthcare India Ltd, Strides Pharma Science Ltd, Sun Pharma Advanced Research Company Ltd, Sanofi India Ltd.
Valuation & Returns
10 Jul 2026At ₹823.4 a share on 10 Jul 2026, Sudeep Pharma Ltd (SUDEEPPHRM) was valued at a price-to-earnings ratio of 53.36x against an industry P/E of 36.41x and a price-to-book of 18.95x on a book value of ₹43.46 per share as of Mar 2025. Solomo computes return on equity of 35.51% and return on capital employed of 37.37% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 53.36x
- Industry P/E
- 36.41x
- P/B
- 18.95x
- EPS (TTM)
- ₹15.43
- Book value / share
- ₹43.46
- ROE
- 35.51%
- ROCE
- 37.37%
- ROA
- 24.3%
- Debt / equity
- 0.28x
- Dividend yield
- 0.18%
- EBITDA margin
- 39%
- 52-week range
- ₹524.95 – ₹893.4
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Sudeep Pharma Ltd (SUDEEPPHRM) reported revenue of ₹642 crore, net profit of ₹174 crore and earnings per share of ₹15.31. That compares with revenue of ₹502 crore and net profit of ₹139 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹182 crore and net profit ₹49 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 343 | 429 | 459 | 502 | 642 |
| Net profit (₹ cr) | 50 | 62 | 133 | 139 | 174 |
| EPS (₹) | 356.04 | 442.27 | 945.21 | 14.27 | 15.31 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 23.73% | 1.13% | 9.30% |
| Profit growth | 39.63% | 22.33% | 4.13% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 76.15% of Sudeep Pharma Ltd (SUDEEPPHRM) (unchanged from the previous quarter), foreign institutional investors (FII) hold 1.81% and domestic institutional investors (DII) hold 15.65%. Market capitalisation was ₹9,300 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2025.
Largest disclosed public shareholders in Jun 2026: Nuvama Crossover Opportunities Fund - Series Iii 2.95%, Nuvama Crossover Opportunities Fund - Series Iii A . 2.57%, Nuvama Crossover Opportunities Fund - Series Iii B . 2.14%, Axis Mutual Fund Trustee Limited A/C Axis Mutual Fund A/C Axis Small Cap Fund 1.85%, Mukul Mahavir Agrawal 1.33%, Sbi Healthcare Opportunities Fund 1.2%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 76.15% | - | 1.81% | 15.65% | 23.85% |
| Mar 2026 | 76.15% | - | 1.55% | 18.11% | 23.85% |
| Dec 2025 | 76.15% | - | 1.67% | 17.6% | 23.85% |